靶向治疗在晚期肾癌中的应用现状和研究进展

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (730 KB)
输出: BibTeX | EndNote (RIS)

摘要近年来对于晚期肾癌的治疗手段层出不穷,而靶向治疗代表了当前治疗的总趋势。靶向治疗是通过干预肿瘤相关信号传导通路来抑制肿瘤的生长,可显著延长晚期肾癌患者的无进展生存期和总生存期,改善患者的预后。目前用于临床的靶向药物主要分为酪氨酸激酶抑制剂、mTOR抑制剂和单克隆抗体,每种药物都有各自的作用机制和适用范围。本文就各种靶向药物在晚期肾癌中的应用现状和研究进展做一综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	范阳
	张旭

关键词 ：肾癌, 靶向治疗, 预后

Abstract：Although various treatments for advanced renal cancer have been emerging in recent years, targeted therapy represents the leading trend of all strategies. Targeted therapy can inhibit tumor growth through disrupting tumor-related signalling pathways, thus significantly prolong progression-free survival and overall survival of advanced renal cancer patients and improve their prognosis. At present, the targeted drugs in clinical use include tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and monoclonal antibodies, where each drug has its own mechanism of action and range of application. This review summarizes the application status and research progress of targeted therapy in advanced renal cancer.

Key words： renal cancer targeted therapy prognosis

收稿日期: 2015-07-09

ZTFLH:

R737.11

基金资助:国家高技术研究发展计划(863计划)(2012AA02101 和2014AA020607)

通讯作者: 张旭 E-mail: xzhang@foxmail.com

引用本文:

范阳,张旭. 靶向治疗在晚期肾癌中的应用现状和研究进展[J]. 微创泌尿外科杂志, 2015, 4(5): 315-320.
Fan Yang, Zhang Xu. Application status and research progress of targeted therapy in advanced renal cancer. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2015, 4(5): 315-320.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract822.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2015/V4/I5/315

[1]Siegel RN, Naishadham D, Jemal A. Cancer statistics,2012. CA Cancer J Clin, 2012, 62(1): 10-29.
[2]Amato JR. Chemotherapy for renal cell carcinoma. Semin Oncol, 2000, 27(2): 177-186.
[3]Rohrmann K, Staehler M, Haseke N, et al. Immunotherapy in metastatic renal cell carcinoma. World J Urol, 2005, 23(3): 196-201.
[4]Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal cell carcinoma. Nat Rev Clin Oncol, 2010, 7(5): 277-288.
[5]Bukowski RM. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol, 2012, 2:13.
[6]Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64(19):7099-7109.
[7]Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005, 92(10):1855-1861.
[8]Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27(8): 1280-1289.
[9]Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 2009, 27(20): 3312-3318.
[10]Bhargava P. VEGF kinase inhibitors:how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol, 2009, 297(1): R1-R5.
[11]Santoni M, Conti A, De Giorgi U, et al. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer, 2014,135(4): 763-773.
[12]Mulder SF, Bertens D, Desar IM, et al. Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients:a cross sectional study. BMC Cancer, 2014,14: 219.
[13]Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 2003, 9(1): 327-337.
[14]Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24(1): 16-24.
[15]Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356(2): 115-124.
[16]Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 2011, 103(9): 763-773.
[17]Park SJ, Lee JL, Park I, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy, 2012, 58(6): 468-474.
[18]Poprach A, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a National registry-based study. Ann Oncol, 2012, 23(12): 3137-3143.
[19]Keisner SV, Shah SR. Pazopanib:the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs, 2011, 71(4): 443-454.
[20]Bukowski RM. Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res, 2011, 3: 273-285.
[21]Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res, 2009, 15(12): 4220-4227.
[22]Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010, 28(6):1061-1068.
[23]Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer, 2013, 49(6): 1287-1296.
[24]Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med, 2013, 369(8): 722-731.
[25]Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res, 2008,14(22): 7272-7283.
[26]Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol, 2005, 23(24): 5474-5483.
[27]Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol, 2007, 8(11): 975-984.
[28]Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, 2011, 378(987): 1931-1939.
[29]Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol, 2013, 14(6): 552-562.
[30]Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol, 2013, 14(13): 1287-1294.
[31]Fischer A, Wu S, Ho AL, et al. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs, 2013, 31(3): 787-797.
[32]Cowey CL. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma. Drug Des Devel Ther, 2013, 7: 519-527.
[33]Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res, 2006, 66(18): 9134-9142.
[34]Eskens FA, De Jonge MJ, Bhargava P, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res, 2011, 17(22): 7156-7163.
[35]Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol, 2012, 30(14): 1678-1685.
[36]Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol, 2013, 31(30): 3791-3799.
[37]Angevin, E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res, 2013, 19(5): 1257-1268.
[38]Escudier B, Grünwald V, Ravaud A, et al. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res, 2014, 20(11): 3012-3022.
[39]Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(3): 286-296.
[40]Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol, 2005, 16(4): 525-537.
[41]Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma:focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol, 2010,4:143-154.
[42]Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol, 2004, 22(12): 2336-2347.
[43]Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol, 2004, 22(5): 909-918.
[44]Hudes, G. Temsirolimus,interferon alfa,or both for advanced renal-cell carcinoma. N Engl J Med, 2007, 356(22): 2271-2281.
[45]Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2014, 32(8): 760-767.
[46]Barthélémy P, Hoch B, Chevreau C, et al. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Crit Rev Oncol Hematol, 2013, 88(1): 42-56.
[47]O'donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol, 2008, 26(10): 1588-1595.
[48]Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer, 2009, 115(11): 2438-2446.
[49]Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 2010, 116(18): 4256-4265.
[50]Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol, 2001, 19(3): 843-850.
[51]Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003, 349(5): 427-434.
[52]Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007, 370(965): 2103-2111.
[53]Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol, 2010, 28(13): 2137-2143.
[54]Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of Anti-PD-1 antibody in cancer. N Engl J Med, 2012, 366(26): 2443-2454.
[55]Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 2010, 28(19): 3167-3175.